Research Call 2021-2022
Muscular Dystrophy Ireland (MDI) is pleased to announce a call for research proposals under the Health Research Charities Ireland (HRCI) and Health Research Board (HRB) Joint Research Fund. Projects funded under this call will begin in September 2022.
Opening Date: 20th August 2021
Closing date for pre-application form: 30th September 2021
Closing date for full applications (if shortlisted): 12th November 2021
Duration of Funding: 12 to 36 months
Level of funding: Up to €50,000 per year
About Muscular Dystrophy Ireland
Muscular Dystrophy Ireland aims to provide information and support to people with neuromuscular conditions and their families through a range of support services. Our objective is to promote through practical empowerment, independent living for people with the condition muscular dystrophy. Muscular Dystrophy Ireland supports advocating for services to enable people with neuromuscular conditions to fully participate in society and to live a life of their own choosing. Muscular Dystrophy Ireland is also committed to supporting and funding research into neuromuscular conditions.
Our Research Strategy and Priorities
Muscular Dystrophy Ireland is committed to supporting researchers and clinicians to carry out the best quality research into neuromuscular conditions.
We aim to:
- Gain a greater understanding of neuromuscular conditions in order to develop potential treatments and ensure a route for clinical trials
- Support more studies into ultra-rare conditions
- Facilitate quality of life research.
Our research priorities are to:
- Better understand the causes, diagnosis, and treatment for neuromuscular conditions
- Understand mechanism of action of Muscular Dystrophies
- Improve quality of life
- Support translation of research from the laboratory to clinical setting
- Improve muscle and motor function, mental health, cognition, coordination, fatigue, gut function, cardiovascular health, respiratory health, gene therapy, genomics, nutrition
Areas of research
MDI encourages proposals for all types of research including basic, clinical, psychosocial and health services research. We seek proposals relating to any of the following neuromuscular conditions
- Becker muscular dystrophy
- Bethlem myopathy
- Central core disease (congenital myopathy)
- Charcot-Marie-Tooth (and related hereditary motor and sensory neuropathies)
- Congenital muscular dystrophy
- Congenital myasthenic syndromes
- Congenital myotonic dystrophy
- Duchenne muscular dystrophy
- Emery-Dreifuss muscular dystrophy
- Facioscapulohumeral muscular dystrophy
- Fibre-type disproportion (congenital myopathy)
- Fibrodysplasia ossificans progressiva (FOP)
- Inclusion body myositis
- Juvenile dermatomyositis
- Limb-girdle muscular dystrophy (LGMD1B, LGMD1C, LGMD2A, LGMD2B, LGMD2I)
- Manifesting carriers of Duchenne muscular dystrophy
- McArdle’s Disease
- Merosin-deficient congenital muscular dystrophy (MDC1A)
- Metabolic disorders
- Minicore (multicore) congenital myopathy
- Mitochondrial myopathies
- Myasthenia gravis
- Myotonic dystrophy
- Myotubular (centronuclear) congenital myopathy
- Nemaline congenital myopathy
- Oculopharyngeal muscular dystrophy
- Periodic paralysis
- Pompe Disease
- Rigid spine syndrome
- Sarcoglycanopathies (LGMD2C, LGMD2D, LGMD2E, LGMD2F)
- Sarcoid myopathy
- Spinal muscular atrophy (SMA type 1, SMA type 2, SMA type 3, adult onset SMA or type 4 SMA)
- Spinal bulbar muscular atrophy (also known as Kennedy’s Disease)
- Ullrich congenital muscular dystrophy.
In order to better streamline the application process for both Muscular Dystrophy Ireland and for applicants, we ask applicants to complete and submit the ‘Pre-application’ form (below) by 30th September 2021 at 5pm. Applicants should not complete the Full HRCI/HRB Application Form at this stage. However, both the full HRCI/HRB Application Form and HRCI/HRB Instructions to Applicants are available below for reference. We strongly recommend that applicants review the HRCI/HRB Instructions to Applicants (including the notes on exclusions) as well as the additional Muscular Dystrophy Ireland Guidance Notes prior to beginning an application.
Following an internal review of all ‘pre-applications’ received, applicants will be notified of the shortlisting outcome on 14th October. Shortlisted applicants will then be invited to submit the full application form by 12th November. Please see the Muscular Dystrophy Ireland Guidance Notes below for more information.
Stage 1: Internal review of pre-application submissions to develop shortlist for full applications
Stage 2: International peer review of full applications including applicants’ Right-to-Reply
Stage 3: Evaluation and ranking by Muscular Dystrophy Ireland Research Committee
Stage 4: Highest ranking proposals submitted for consideration under the HRCI /HRB Joint Funding Scheme.
The successful project(s) will be funded jointly by Muscular Dystrophy Ireland and the HRB, beginning in September 2022.
For application forms or more details on the HRCI/HRB Joint Funding Scheme, please see the links below.
For further information, please contact: